This firm currently holds 646.93 M in liabilities with Debt to Equity (D/E) ratio of 810.0, indicating Clovis Oncology may have difficulties to generate enough cash to satisfy its financial obligations. The company has a current ratio of 1.65, which is within standard range for the sector. On a scale of 0 to 100, Clovis Oncology holds a performance score of 8. The firm shows a Beta (market volatility) of 0.3783, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Clovis's beta means in this case. As returns on the market increase, Clovis Oncology returns are expected to increase less than the market. However, during the bear market, the loss on holding Clovis Oncology will be expected to be smaller as well. Although it is vital to follow Clovis Oncology historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-seven technical indicators for Clovis Oncology, which you can use to evaluate the performance of the firm. Please makes use of Clovis Oncology maximum drawdown, as well as the relationship between the skewness and day typical price to make a quick decision on whether Clovis Oncology price patterns will revert.